Bidirectional effects of dexmedetomidine on human platelet functions in vitro. by Kawamoto, Shuji et al.
Title Bidirectional effects of dexmedetomidine on human plateletfunctions in vitro.
Author(s)Kawamoto, Shuji; Hirakata, Hideo; Sugita, Naoko; Fukuda,Kazuhiko




© 2015. This manuscript version is made available under the
CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/; The full-
text file will be made open to the public on 5 December 2016
in accordance with publisher's 'Terms and Conditions for Self-
Archiving'.; この論文は出版社版でありません。引用の際
には出版社版をご確認ご利用ください。This is not the




















Psychiatry, Kyoto University Hospital, 54 Shogoin Kawahara-
cho, Sakyo-ku, Kyoto 606-8507, Japan  
b
Department of Anesthesia, National Hospital Organization Kyoto Medical Center, 1-1 
Fukakusa mukaihata-cho, Fushimi-ku, Kyoto 612-8555, Japan 
 
*Corresponding Author. 
 E-mail address:  shuji-kawamoto@ares.eonet.ne.jp (S. Kawamoto) 
Manuscript




Platelets express the imidazoline (I)-receptor, I1 and I2, as well as the α2-adrenoceptor. Although 
dexmedetomidine, a selective α2-adrenoceptor agonist with some affinity for the I-receptor is 
expected to affect platelet function, the effects of dexmedetomidine on platelet functions remain 
unclear. In the present study, we investigated the effects of dexmedetomidine on human platelet 
functions in vitro. The effects of dexmedetomidine on platelet aggregation were examined using 
aggregometers. The formation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) in platelets was measured by an enzyme immunoassay. In addition, P-
selectin expression in platelets was estimated by flow cytometry. Dexmedetomidine enhanced 
and suppressed platelet aggregation in the absence and the presence of yohimbine, an α2-
antagonist, respectively. Efaroxan, an I1-antagonist, and methylene blue, a soluble guanylate 
cyclase inhibitor, abolished the suppressive effect of dexmedetomidine, whereas idazoxan, an I2-
antagonist, showed no effect. Dexmedetomidine suppressed cAMP formation and enhanced P-
selectin expression in platelets, and these effects were inhibited by yohimbine. 
Dexmedetomidine increased cGMP formation in platelets in the presence of yohimbine, and this 
increase was suppressed by efaroxan. These results demonstrated that dexmedetomidine has both 
enhancing and suppressive effects on human platelet functions through its action on the α2-
adrenoceptor and on the I1-receptor, respectively. 
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1. Introduction  
 
     Because platelets are essential for maintaining hemostasis, information on the effects of 
perioperatively used drugs including anaesthetics on platelet functions is indispensable for 
patient care. Previously, the inhibitory effects of volatile anaesthetics on human platelet 
aggregation were shown in both in vitro (Hirakata et al., 1995; Hirakata et al., 1996) and in vivo 
studies (Hirakata et al., 1997). With respect to intravenous anaesthetics, we have reported that 
propofol has both enhancing and suppressive effects on human platelet aggregation in vitro 
(Hirakata et al., 1999), and ketamine inhibits human platelet aggregation possibly by suppression 
of inositol trisphosphate formation (Nakagawa et al., 2002). However, the effects of a number of 
drugs, which have recently become clinically applicable, on platelet functions remain to be 
examined.   
    It has not been extencively examined whether dexmedetomidine, an R (+)-enantiomer of 
medetomidine with a highly selective affinity for the α2-adrenoceptor, that is clinically used for 
sedation and analgesia (Kamibayashi and Maze, 2000; Ramsay and Luterman, 2004), affects 
human platelet function. As it was reported that adrenaline can potentiate platelet aggregation by 
activation of the α2-adrenoceptor in platelets (Lanza and Cazenave, 1985), it is probable that 
dexmedetomidine also affects platelet functions. Dexmedetomidine also exhibits some affinity 
for imidazoline (I)-receptors, which are expressed in various cells, including platelets, and are 
suggested to participate in many physiological functions (Dahmani et al., 2008; Ernsberger et al., 
1997a; Ernsberger and Haxhiu, 1997b; Savola and Savola, 1996; Virtanen et al., 1988; Wikberg 
 4 
et al., 1991). The existence of I1- and I2-receptors in human platelets (Michel et al., 1990; Piletz 
and Sletten, 1993; Piletz et al., 1996), and the suppressive effect of imidazoline agents on rabbit 
platelet aggregation via I-receptors (Yokota et al., 2013), may suggest that dexmedetomidine can 
affect human platelet functions via I-receptors. It is important clinically as well as 
pharmacologically to examine the effect of dexmedetomidine on platelet functions, because 
dexmedetomidine is often administered to critically ill patients whose platelet number in the 
blood is seriously decreased by a variety of pathophysiological mechanisms,. 
The aim of this study was to evaluate the effects of dexmedetomidine on human platelet 
functions and to elucidate the underlying mechanisms especially concerning the α2-
adrenoreceptor and I-receptors. Our results demonstrate that dexmedetomidine has both 
enhancing and suppressive effects on human platelet functions through action on the α2-
adrenoceptor and the I1-receptor, respectively.
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2. Materials and methods  
2.1. Platelet preparation  
     Written informed consent was obtained from subjects, and the protocol was approved by 
the ethics committee of Kyoto University Hospital. Venous blood was obtained by venipuncture 
of antecubital veins from 15 healthy volunteers who had not taken any medication for at least 
two weeks before blood sampling. The blood was mixed with 10% volume of 3.8% tri-sodium 
citrate. Platelet-rich plasma (PRP) was prepared by centrifugation of the blood sample at 160 g 
for 10 min at room temperature and collection of the supernatant. The remaining lower portion 
was further centrifuged at 1600 g for 30 min at room temperature, and the clear supernatant was 
used as platelet-poor plasma (PPP).  
 
2.2. Chemicals and drugs 
     Dexmedetomidine and idazoxan were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Yohimbine and methylene blue were purchased from Nacalai Tesque (Kyoto, 
Japan). Levomedetomidine, an S (-)-enantiomer of medetomidine was kindly supplied by Orion 
Corporation (Espoo, Finland). Adenosine diphosphate (ADP) and efaroxan were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), and Tocris Bioscience (Bristol, UK), respectively. 9, 11-
epithio-11, 12-methanothromboxane A2 (STA2) was provided by Ono Pharmaceutical (Osaka, 
Japan). Peridinin Chlorophyll Protein (PerCP)-labeled anti-CD61 antibody, Phycoerythrin (PE)-
labeled anti-CD62P (P-selectin) antibody and PE-labeled IgG for control were obtained from 
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Becton Dickinson (San Diego, CA, USA). All other chemicals were of analytical grade. We 
confirmed that all buffers or solvents for diluting materials in our experiments showed no effect 
on the results. 
 
2.3. Measurement of agonist-induced and spontaneous platelet aggregation 
     An aliquot of PRP was pipetted into a cylindrical cuvette containing either 
dexmedetomidine or levomedetomidine and incubated at 37˚C for 3 min in the presence or 
absence of various antagonists (yohimbine, efaroxan, idazoxan and methylene blue). Then, the 
sample was stirred constantly at 37˚C with a magnetic bar at a rate of 1000 rpm. ADP-induced 
aggregation was measured for 7 min as a change in light transmission using an aggregometer 
(MCM Hema Tracer 212; MC Medical, Tokyo, Japan). The light transmission of PPP was taken 
as 100%, and aggregation was expressed as percentage of the light transmission. Spontaneous 
platelet aggregation in PRP was measured without any agonists for 7 min using an ultra-sensitive 
platelet aggregation analyzer (PA-200, Kowa, Tokyo, Japan), and expressed as light scattering 
intensity.  
 
2.4. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) 
assays 
     Washed platelets were used in in cAMP and cGMP assays to exclude the possible effects of  
other blood cells on the results. PRP in a 10% volume of 100 mM ethylenediaminetetraacetic acid 
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(EDTA) was centrifuged at 900 g for 15 min at 4˚C. The pellet was suspended in the wash buffer 
containing 8 mM Na2HPO4, 2 mM NaH2PO4, 10 mM EDTA, 135 mM NaCl and 5 mM KCl, and 
centrifuged again at 900 g for 15 min at 4˚C. The platelets were finally suspended at a 
concentration of either 10
6
 platelets μl-1 or 2.5 x 106 platelets μl-1 for the cAMP and cGMP assays, 
respectively, in the assay buffer containing 10 mM N-2-Hydroxyethylpiperazine-N'-2'-
ethanesulfonic acid (HEPES), 0.5 mM Na2HPO4, 145 mM NaCl, 5mM KCl, and 6 mM glucose.  
     For the cAMP assay, 100 μl of the platelet suspension was incubated at 37˚C for 3 min in a 
cylindrical cuvette, and then stirred with a magnetic bar at a rate of 1,000 rpm at 37˚C. Platelets 
were stimulated with 0.1 μM STA2, a stable thromboxane A2 analog, at 37˚C for 7 min in the 
presence or absence of either dexmedetomidine or
 
levomedetomidine with or without yohimbine. 
STA2 was used for stimulation in this experiment, because washed platelets cannot be activated 
by ADP. For the cGMP assay, 100 μl of the platelet suspension containing yohimbine was 
incubated at 37˚C for 3 min in a cylindrical cuvette in the presence or absence of either 
dexmedetomidine or rilmenigine with or without efaroxan, and then stirred with a magnetic bar at 
a rate of 1,000 rpm at 37˚C for 7 min. In both the cAMP and cGMP assays, the reaction was 
terminated by adding 10% volume of 0.1 M ice-cold HCl, and the samples were kept at -20˚C 
until measurement.  
     The cAMP and cGMP measurements were performed using commercially available enzyme 
immunoassay kits (Cyclic AMP EIA Kit No. 581001 and Cyclic GMP EIA Kit No. 581021 
Cayman Chemical, Michigan, USA), according to the manufacturer’s protocol. 
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2.5. Flow cytometry analysis for P-selectin expression on ADP-stimulated and unstimulated 
platelets 
     PRP was diluted 10-fold with phosphate-buffered saline (PBS) containing 139 mM NaCl, 
8.1 mM NaHPO4, 1.5 mM KH2PO4, and 2.7 mM KCl. For the ADP-stimulated platelet analysis, 
an aliquot of diluted PRP was incubated with either dexmedetomidine or levomedetomidine in 
the presence or absence of yohimbine at room temperature for 30 min. Some samples were co-
incubated with ADP. For the analysis of unstimulated platelets, an aliquot of diluted PRP was 
pipetted into a cylindrical cuvette and incubated at 37˚C for 3 min with either dexmedetomidine 
or levomedetomidine in the presence or absence of yohimbine. Then, the samples were stirred 
constantly with a magnetic bar at a rate of 1,000 rpm at 37˚C for 7 min and incubated at room 
temperature for 30 min without stirring. In both assays, samples were fixed with ice-cold 1% 
formaldehyde for 60 min on ice and washed twice with ice-cold PBS by centrifugation at 900 g 
for 15 min at 4˚C. The pellet was suspended in 100 μl PBS at 4˚C. Then, 5 μl of the platelet 
suspension was co-incubated with PerCP-labeled anti-CD61 antibody and PE-labeled anti-
CD62P (P-selectin) antibody in a final volume of 50 μl adjusted with PBS for 60 min at room 
temperature in the dark. PE-labeled IgG was used to estimate the nonspecific binding. The 
reaction was stopped by adding ice-cold PBS. Samples were analyzed using a fluorescence-
activated cell sorting (FACS) Calibur instrument (Becton Dickinson, San Jose, CA, USA). For 
each sample, data from 10,000 platelets were collected. Platelets were identified by forward and 
side scatter intensity and by CD61 expression. P-selectin expression levels on activated platelet 
surface membranes were recorded as the mean fluorescent intensity (MFI) of PE.  
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2.6. Statistical Analysis 
     All data are expressed as mean ± standard deviation (SD) of three to five sepatate 
experiments. The group variances were tested by the Brown-Forsythe test, and statistically equal. 
All data were compared with one-way analysis of variance (ANOVA), followed by the Dunnett’s 
test. Statistical analyses were performed using Prism 5.0 software (GraphPad Software, San 
Diego, CA, USA). P values less than 0.05 were considered to indicate statistical significance.
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3. Results  
3.1. Effects of dexmedetomidine on platelet aggregation 
     Dexmedetomidine (10-500 ng ml
-1
) enhanced platelet aggregation induced by 0.5 μM 
ADP in a dose-dependent manner, while levomedetomidine (500 ng ml
-1
), an S (-)-enantiomer of 
medetomidine with an α2-adrenoceptor binding affinity much lower than that of 
dexmedetomidine (Jansson et al., 1994), had no significant effect (Fig. 1A). We next aimed to 
pharmacologically analyze which receptor is involved in the effect of dexmedetomidine on 
platelet aggregation. We used 1.5 μM ADP for stimulation in this experiment, because platelet 
aggregation induced by 0.5 μM ADP was too low to examine the effect of antagonists on the 
enhancing effect. Yohimbine alone did not affect ADP-induced platelet aggregation (data not 
shown). Fig. 1B shows that the enhancing effect of dexmedetomidine on platelet aggregation 
was abolished by yohimbine, suggesting that dexmedetomidine activates platelet aggregation 
through the activation of the α2-adrenoceptor in the presence of ADP stimulation. Interestingly, 
platelet aggregation in the presence of dexmedetomidine and yohimbine was significantly lower 
than that of the control level, indicating that dexmedetomidine has a suppressive effect on 
platelet aggregation by a mechanism other than through the α2-adrenoceptor. Efaroxan, an I1-
antagonist, abolished the suppressive effect of dexmedetomidine in the presence of yohimbine, 
but idazoxan, an I2-antagonist, did not (Fig. 1B). This result suggests that dexmedetomidine 
suppresses platelet aggregation via the I1-receptor. Methylene blue, a soluble guanylate cyclase 
(GC) inhibitor, was used to examine whether dexmedetomidine suppresses platelet aggregation 
by activation of GC. Methylene blue alone did not affect ADP-induced platelet aggregation (data 
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not shown), but abolished the suppressive effect of dexmedetomidine on ADP-induced platelet 
aggregation in the presence of yohimbine (Fig. 1B), indicating that GC activation mediates the 
suppressive effect of dexmedetomidine.   
     We next examined whether dexmedetomidine affects platelet aggregation in the absence of 
stimulation. Fig. 1C demonstrates that dexmedetomidine (10 ng ml
-1
) enhanced spontaneous 
platelet aggregation, while levomedetomidine (100 ng ml
-1
) had no significant effect. 
Furthermore, the enhancing effect of dexmedetomidine was suppressed by yohimbine. Thus, our 
results show that dexmedetomidine activates platelet aggregation through activation of the α2-
adrenoceptor regardless of the presence or absence of ADP stimulation.  
 
3.2. Mechanism of α2-adrenoceptor-mediated platelet activation  
     It is well known that a decrease in the cAMP levels plays a major role in the platelet-
activating effects of the α2-adrenoceptor (Keularts et al., 2000). Fig. 2A shows that 
dexmedetomidine (10 ng ml
-1
) suppressed cAMP formation, and this effect of dexmedetomidine 
was blocked by yohimbine. Levomedetomidine (100 ng ml
-1
) did not significantly affect cAMP 
formation with or without yohimbine (Fig. 2B). These results indicate that dexmedetomidine 
suppresses cAMP formation via the α2-adrenoceptor, which probably results in the enhancement 
of platelet aggregation.  
     Next, we assessed P-selectin expression to analyze the effect of dexmedetomidine on 
platelet functions other than platelet aggregation, because P-selectin expression increases on the 
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surface of activated platelets in the process of granule secretion (Furie et al., 2001). Fig. 3 shows 
that dexmedetomidine (10-100 ng ml
-1
) enhanced P-selectin expression on both ADP-stimulated 
and non-stimulated platelet surfaces in a dose-dependent manner, and the enhancing effect was 
abolished by yohimbine. Levomedetomidine (up to 100 ng ml
-1
) did not significantly affect 
surface P-selectin expression (Fig. 3). This result indicates that dexmedetomidine not only 
enhances platelet aggregation but also increases P-selectin expression via the α2-adrenoceptor in 
the presence or absence of ADP stimulation. 
 
3.3. Mechanism of I1-receptor-mediated inhibition of platelet aggregation 
     To elucidate the mechanism for the GC activation involved in the dexmedetomidine-
induced inhibition of platelet aggregation mediated by the I1-receptor (see above), we tested 
whether cGMP is increased by dexmedetomidine. Fig. 4 demonstrates that dexmedetomidine (10-
100 ng ml
-1
) increased cGMP levels in a dose-dependent manner in the presence of yohimbine. 
Rilmenigine (100 μM), an I1-agonist, also increased cGMP levels in the presence of yohimbine. 
The increase in cGMP production induced by both dexmedetomidine and rilmenigine was 
abolished by efaroxan. These results suggest that dexmedetomidine increases cGMP levels via the 
I1-receptor, leading to GC activation and suppression of platelet aggregation. 
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4. Discussion 
     In this study, we aimed to elucidate the effect of dexmedetomidine on human platelet 
functions in vitro. The results demonstrate that dexmedetomidine potentiates and suppresses 
human platelet function via the α2-adrenoceptor and the I1-imidazoine receptor, respectively, as 
depicted in Fig. 5. This is the first report showing that dexmedetomidine produces a bidirectional 
effect on human platelet.  
     Activation of the α2-adrenoceptor induces inhibition of adenylate cyclase (AC) and 
reduction of cAMP formation from adenosine triphosphate (Limbird, 1988). It has been reported 
that reduction in cAMP levels induces platelet activation by suppressing cAMP-dependent 
phosphorylation of the inositol trisphosphate receptor and potentiating calcium release from the 
endoplasmic reticulum (Keularts et al., 2000). The results in this study showed that 
dexmedetomidine enhanced ADP-induced platelet aggregation and suppressed platelet cAMP 
formation via the α2-adrenoceptor. Together with previous reports, it is suggested that 
dexmedetomidine activates the α2-adrenoceptor leading to suppression of cAMP formation, an 
increase in cytosolic calcium levels, and finaly enhances platelet activation.   
     Spontaneous platelet aggregation, generally defined as the formation of small-sized 
aggregates without any stimulation under constant stirring (Ozaki et al., 1994), could be 
considered as the initial aggregation step leading to thrombus formation. The spontaneously 
formed small-sized aggregates of platelets play a pivotal role in cardiovascular events and 
predict the occurrence of these events more reliably than the change in the agonist-induced 
aggregation (Kajiwara et al., 2001; Miyamoto et al., 2000). On the other hand, P-selectin, one of 
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the adhesion molecules involved in the interaction between platelets and other cells, stabilizes 
the initial platelet aggregates in human platelets in vitro (Merten and Thiagarajan, 2000), and 
contributes to the increase and stabilization of arterial thrombi (Christersson et al., 2008; 
Yokoyama et al., 2005). Clinical studies demonstrated that platelet surface P-selectin expression 
is increased in the context of arteriosclerosis, ischemic stroke and peripheral arterial disease 
(Burger and Wagner, 2003; Marquardt et al., 2002; Zeiger et al., 2000). Since our results 
demonstrated that dexmedetomidine enhances spontaneous aggregation and P-selectin 
expression, it might be possible that dexmedetomidine enhances thrombus formation particularly 
in patients with high blood coagulability. 
     We showed that dexmedetomidine suppressed ADP-induced platelet aggregation via the 
I1-receptor. The I1-receptor is expressed in platelets, and neural and epithelial cells (Dahmani et 
al., 2008; Piletz and Sletten, 1993; Piletz et al., 1996; Savola and Savola, 1996; Virtanen et al., 
1988; Wikberg et al., 1991), but the physiological functions are not fully understood. Although 
signal transduction mechanisms activated by the I1-receptor remain to be clarified, we 
hypothesized that cGMP is involved in the I1-receptor-mediated inhibition of platelet 
aggregation, because an increase in the intracellular cGMP level can inhibit platelet aggregation 
(Smolenski, 2012), and clonidine increases cGMP production by the action on the I-receptors in 
the rat adrenal gland (Regunathan et al., 1990). Our results demonstrated that the suppressive 
effect of dexmedetomidine on ADP-inducded platelet aggregation was reduced by methylene 
blue, a GC inhibitor, and that cGMP formation was increased by dexmedetomidine, which was 
inhibited by efaroxan. Thus, it is suggested that dexmedetomidine suppresses ADP-induced 
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platelet aggregation by I1-receptor activation resulting in GC activation and an increase in cGMP 
formation. Further study is necessary to elucidate the mechanism of I1-receptor-mediated GC 
activation.   
     Although there have been several reports on the effects of dexmedetomidine on bleeding 
during surgery, the results are not consistent and the mechanism for its effect on bleeding has not 
been fully explored. Durmus et al. (2007) demonstrated that dexmedetomidine decreased 
bleeding in patients undergoing elective tympanoplasty and septorhinoplasty under general 
anesthesia. In contrast, Mizrak et al. (2013) reported that dexmedetomidine increased bleeding in 
pediatric patients undergoing adenotonsillectomy. Our results demonstrated that 
dexmedetomidine has both enhancing and suppressive effects on platelet functions, and that a 
drug with α2-antagonist-like activity affects which of the two opposite effects becomes evident. 
Therefore, the effects of dexmedetomidine on bleeding might depend on whether 
dexmedetomidine is administered together with drugs blocking the α2-adrenoreceptor, such as 
yohimbine, a selective α2-antagonist used for treatment of male sexual dysfunction (Tam et al., 
2001), and phenoxybenzamine, a non-selective α-antagonist used for perioperative management 
of pheochromocytoma (Agrawal et al., 2014). The effects of dexmedetomidine on hemostasis 
might be more apparent in patients whose platelet number in the blood is seriously decreased by 
a variety of pathophysiological mechanisms. Further studies are necessary to clarify whether 
dexmedetomidine actually affects platelet functions and hemostasis in the clinical setting. 
     There are some limitations in this study. The first limitation is that the concentration of 
dexmedetomidine used in our study was apparently higher than the usual therapeutic 
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concentration range (0.4-1.2 ng ml
-1
) (Venn et al., 2002). In fact, Kose et al. (2013) showed that 
0.4-1.2 ng ml
-1
 of dexmedetomidine had no effect on platelet aggregation induced by ADP, 
collagen, and epinephrine in vitro. However, because it was reported that the plasma 
concentration of dexmedetomidine can reach 10 ng ml
-1
 in patients with liver dysfunction and the 
elimination half-life and context-sensitive half-time of dexmedetomidine are prolonged in the 
elderly and by hypoalbuminemia (Iirola et al., 2012), it might be possible that dexmedetomidine 
affects platelet functions in the clinical setting. The second limitation is that our study was 
performed in vitro and could not evaluate the effects of blood flow, blood vessels, shear stress on 
platelets, and the interactions between platelets and other blood cells. To clarify the involvement 
of these factors in the effect of dexmedetomidine on hemostasis, an in vivo study is required. The 
third limitation is that we analyzed the effect of dexmedetomidine on platelet aggregation 
induced by only ADP. Because we cannot exclude the possibility that the effect of 
dexmedetomidine is dependent on the type of stimulation, we should examine the effect of 
dexmedetomidine on platelets stimulated with other agonists including collagen and thrombin in 
future.  
 
5. Conclusions  
     The present study demonstrated that dexmedetomidine has both enhancing and suppressive 
effects on platelet functions in vitro. Our data suggest that the enhancing effect is mediated by 
activation of the α2-adrenoceptor and inhibition of AC, while the suppressive effect is mediated 
by activation of the I1-receptor and GC. 
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Figure legends  
 
Fig. 1. Effects of dexmedetomidine on human platelet aggregation. (A) Effects of dexmedetomidine 
(DEX; 1-500 ng ml
-1
) and levomedetomidine (LEVO; 500 ng ml
-1
) on platelet aggregation 
induced by 0.5 μM ADP. The data are expressed as mean ± SD (n = 5). *P < 0.05 vs. DEX (-), 
LEVO (-). (B) Effects of dexmedetomidine (DEX; 10 ng ml
-1
) on platelet aggregation induced by 
1.5 μM ADP in the presence and absence of yohimbine (YH; 10 μM), efaroxan (EX; 10 μM), 
idazoxan (IX; 10 μM), and methylene blue (MB; 3 μM). The data are expressed as mean ± SD (n = 
5). *P < 0.05 vs. DEX (-), YH (-), EX(-), IX (-), MB (-). (C) Effects of dexmedetomidine (DEX; 1-
10 ng ml
-1
) and levomedetomidine (LEVO; 100 ng ml
-1
) on spontaneous platelet aggregation in 
the absence and presence of yohimbine (YH; 10 μM). The data are expressed as mean ± SD (n = 
5). *P < 0.05 vs. DEX (-), YH (-), LEVO (-). Dexmedetomidine enhanced both ADP-induced and 
spontaneous platelet aggregation, whereas levomedetomidine showed no effect on platelt 
aggregation. Dexmedetomidine suppressed ADP-induced platelet aggregation in the presence of 
yohimbine, and this effect was abolished by efaroxan and methylene blue.  
 
Fig. 2. Effects of dexmedetomidine (DEX; 10 ng ml
-1
) (A) and levomedetomidine (LEVO; 100 
ng ml
-1
) (B) on cAMP formation in platelets stimulated with 0.1 μM 9, 11-epithio-11, 12-
methanothromboxane A2 (STA2) for 7 min in the presence and absence of yohimbine (YH; 100 
μM). The data are expressed as mean ± SD (n = 3). *P < 0 .05 vs. DEX (-), YH (-). 
Dexmedetomidine suppressed cAMP formation, and this effect was blocked by yohimbine, 
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whereas levomedetomidine did not significantly affect cAMP formation in the presence or 
absence of yohimbine.  
 
Fig. 3. Effect of dexmedetomidine (DEX; 1-100 ng ml
-1
) and levomedetomidine (LEVO; 100 ng 
ml
-1
) on surface P-selectin expression in platelets. Experiments were performed with (A) or 
without (B) stimulation by 10 μM ADP in the presence and absence of yohimbine (YH; 10 μM). 
MFI, mean fluorescence intensity. The data are expressed as mean ± SD (n = 4). *P < 0.05 vs. DEX 
(-), YH (-), LEVO (-). In the presence or absence of ADP stimulation, dexmedetomidine 
enhanced P-selectin expression in a yohimbine-sensitive manner, whereas levomedetomidine did 
not significantly affect P-selectin expression. 
  
Fig. 4. Effect of dexmedetomidine (DEX; 1-100 ng ml
-1) and rilmenigine (RLM; 100 μM) on 
cGMP formation in the presence of yohimbine (YH; 100 μM). Efaroxan (EX; 10 μM) abolished 
the enhancing effect of dexmedetomidine and rilmenigine. The data are expressed as mean ± SD 
(n = 5). *P < 0.05 vs. DEX (-), RLM (-), EX (-). 
 
Fig. 5. Bidirectional effects of dexmedetomidine (DEX) on platelet aggregation. DEX activates 
the α2-adrenoceptor (α2R), leading to suppression of adenylate cyclase and cAMP formation, and 
finaly enhances platelet aggregation. On the other hand, DEX activates guanylate cyclase and 
increases cGMP levels via the I1-imidazoline receptor (I1R), leading to suppression of platelet 
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aggregation. White and black arrows represent the DEX-induced effects involvong α2R and I1R, 
respectively. Upward and downward arrows show activation/increase and inhibition/decrease, 
respectively. The interrupted lines represent the effects of the inhibitors used in this study. 
Yohimbine and efaroxan inhibit the DEX-induced α2- and I1-activation, respectively. Methylene 
blue suppresses guanylate cyclase activity. The dotted line represens the action of rilmenigine, 
which activates I1R leading to increase in cGMP. ATP; adenosine triphosphate, GTP; guanosine 
triphosphate, cAMP; cyclic adenosine monophosphate, cGMP; cyclic guanosine monophosphate. 
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Dear Dr. Nijkamp: 
 
On behalf of my co-authors, I would like to ask you to consider our manuscript entitled "Bidirectional 
effects of dexmedetomidine on human platelet functions in vitro” for publication in the European Journal 
of Pharmacology as an original research report.  
 
Because platelets are essential for keeping hemostasis, information on the effects of perioperatively 
used drugs including anesthetics on platelet functions is indispensable for perioperative patient care. 
This is the first report showing both enhancing and suppressive effects of dexmedetomidine on human 
platelet functions in vitro. Our results suggest that the enhancing effect is mediated by activation of 
the α
2
-adrenoceptor and inhibition of adenylate cyclase, while the suppressive effect is mediated by 
activation of the imidazoline I
1
-receptor and guanylate cyclase. Because dexmedetomidine is 
frequently used for sedation and analgesia for critically ill patients, our results would provide useful 
information for intensive care. We feel that the findings from this study will be of particular interest to 
the readers of the European Journal of Pharmacology. 
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